HCA Healthcare, Inc.
HCA Healthcare, Inc. (HCA) Stock Competitors & Peer Comparison
See (HCA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCA | $526.52 | -1.76% | 117.7B | 18.59 | $28.32 | +0.55% |
| THC | $237.58 | +1.63% | 20.9B | 15.33 | $15.50 | N/A |
| UHS | $229.98 | -1.13% | 14.8B | 10.95 | $21.00 | +0.35% |
| FMS | $22.66 | -7.85% | 13.2B | 15.74 | $1.44 | +3.47% |
| SOLV | $73.42 | +1.06% | 12.7B | 8.43 | $8.71 | N/A |
| ENSG | $212.39 | -0.83% | 12.3B | 36.43 | $5.83 | +0.12% |
| EHC | $104.84 | -1.23% | 10.5B | 18.88 | $5.55 | +0.69% |
| DVA | $150.91 | -0.24% | 10.1B | 15.87 | $9.51 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| CHE | $468.32 | -2.14% | 6.8B | 24.77 | $18.90 | +0.49% |
Stock Comparison
HCA vs THC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, THC has a market cap of 20.9B. Regarding current trading prices, HCA is priced at $526.52, while THC trades at $237.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas THC's P/E ratio is 15.33. In terms of profitability, HCA's ROE is -1.41%, compared to THC's ROE of +0.35%. Regarding short-term risk, HCA is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check THC's competition here
HCA vs UHS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, UHS has a market cap of 14.8B. Regarding current trading prices, HCA is priced at $526.52, while UHS trades at $229.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas UHS's P/E ratio is 10.95. In terms of profitability, HCA's ROE is -1.41%, compared to UHS's ROE of +0.20%. Regarding short-term risk, HCA is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check UHS's competition here
HCA vs FMS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, FMS has a market cap of 13.2B. Regarding current trading prices, HCA is priced at $526.52, while FMS trades at $22.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas FMS's P/E ratio is 15.74. In terms of profitability, HCA's ROE is -1.41%, compared to FMS's ROE of +0.05%. Regarding short-term risk, HCA is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check FMS's competition here
HCA vs SOLV Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SOLV has a market cap of 12.7B. Regarding current trading prices, HCA is priced at $526.52, while SOLV trades at $73.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SOLV's P/E ratio is 8.43. In terms of profitability, HCA's ROE is -1.41%, compared to SOLV's ROE of +0.41%. Regarding short-term risk, HCA is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check SOLV's competition here
HCA vs ENSG Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ENSG has a market cap of 12.3B. Regarding current trading prices, HCA is priced at $526.52, while ENSG trades at $212.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ENSG's P/E ratio is 36.43. In terms of profitability, HCA's ROE is -1.41%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, HCA is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check ENSG's competition here
HCA vs EHC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, EHC has a market cap of 10.5B. Regarding current trading prices, HCA is priced at $526.52, while EHC trades at $104.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas EHC's P/E ratio is 18.88. In terms of profitability, HCA's ROE is -1.41%, compared to EHC's ROE of +0.23%. Regarding short-term risk, HCA is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check EHC's competition here
HCA vs DVA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, DVA has a market cap of 10.1B. Regarding current trading prices, HCA is priced at $526.52, while DVA trades at $150.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas DVA's P/E ratio is 15.87. In terms of profitability, HCA's ROE is -1.41%, compared to DVA's ROE of -1.61%. Regarding short-term risk, HCA is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check DVA's competition here
HCA vs OSH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, HCA is priced at $526.52, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas OSH's P/E ratio is -17.65. In terms of profitability, HCA's ROE is -1.41%, compared to OSH's ROE of +4.64%. Regarding short-term risk, HCA is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check OSH's competition here
HCA vs CHE Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, HCA is priced at $526.52, while CHE trades at $468.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CHE's P/E ratio is 24.77. In terms of profitability, HCA's ROE is -1.41%, compared to CHE's ROE of +0.24%. Regarding short-term risk, HCA is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CHE's competition here
HCA vs OPCH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, OPCH has a market cap of 5.5B. Regarding current trading prices, HCA is priced at $526.52, while OPCH trades at $33.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas OPCH's P/E ratio is 26.84. In terms of profitability, HCA's ROE is -1.41%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, HCA is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check OPCH's competition here
HCA vs LHCG Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, HCA is priced at $526.52, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas LHCG's P/E ratio is 82.83. In terms of profitability, HCA's ROE is -1.41%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, HCA is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check LHCG's competition here
HCA vs BKD Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, BKD has a market cap of 3.6B. Regarding current trading prices, HCA is priced at $526.52, while BKD trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas BKD's P/E ratio is -11.63. In terms of profitability, HCA's ROE is -1.41%, compared to BKD's ROE of -5.24%. Regarding short-term risk, HCA is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check BKD's competition here
HCA vs AMED Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, HCA is priced at $526.52, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AMED's P/E ratio is 39.30. In terms of profitability, HCA's ROE is -1.41%, compared to AMED's ROE of +0.13%. Regarding short-term risk, HCA is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check AMED's competition here
HCA vs LFST Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, LFST has a market cap of 2.8B. Regarding current trading prices, HCA is priced at $526.52, while LFST trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas LFST's P/E ratio is -238.00. In terms of profitability, HCA's ROE is -1.41%, compared to LFST's ROE of -0.01%. Regarding short-term risk, HCA is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check LFST's competition here
HCA vs NHC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, HCA is priced at $526.52, while NHC trades at $157.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas NHC's P/E ratio is 24.34. In terms of profitability, HCA's ROE is -1.41%, compared to NHC's ROE of +0.10%. Regarding short-term risk, HCA is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check NHC's competition here
HCA vs SGRY Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SGRY has a market cap of 2B. Regarding current trading prices, HCA is priced at $526.52, while SGRY trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SGRY's P/E ratio is -11.31. In terms of profitability, HCA's ROE is -1.41%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, HCA is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check SGRY's competition here
HCA vs ADUS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ADUS has a market cap of 1.9B. Regarding current trading prices, HCA is priced at $526.52, while ADUS trades at $105.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ADUS's P/E ratio is 22.58. In terms of profitability, HCA's ROE is -1.41%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, HCA is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check ADUS's competition here
HCA vs SEM Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SEM has a market cap of 1.8B. Regarding current trading prices, HCA is priced at $526.52, while SEM trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SEM's P/E ratio is 18.07. In terms of profitability, HCA's ROE is -1.41%, compared to SEM's ROE of +0.09%. Regarding short-term risk, HCA is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check SEM's competition here
HCA vs AMEH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, HCA is priced at $526.52, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AMEH's P/E ratio is 39.25. In terms of profitability, HCA's ROE is -1.41%, compared to AMEH's ROE of +0.02%. Regarding short-term risk, HCA is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AMEH's competition here
HCA vs MD Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, HCA is priced at $526.52, while MD trades at $20.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas MD's P/E ratio is 10.50. In terms of profitability, HCA's ROE is -1.41%, compared to MD's ROE of +0.20%. Regarding short-term risk, HCA is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check MD's competition here
HCA vs ACHC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ACHC has a market cap of 1.6B. Regarding current trading prices, HCA is priced at $526.52, while ACHC trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ACHC's P/E ratio is 14.80. In terms of profitability, HCA's ROE is -1.41%, compared to ACHC's ROE of +0.03%. Regarding short-term risk, HCA is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check ACHC's competition here
HCA vs HCSG Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, HCA is priced at $526.52, while HCSG trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas HCSG's P/E ratio is 26.42. In terms of profitability, HCA's ROE is -1.41%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, HCA is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check HCSG's competition here
HCA vs AVAH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, HCA is priced at $526.52, while AVAH trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AVAH's P/E ratio is 19.08. In terms of profitability, HCA's ROE is -1.41%, compared to AVAH's ROE of -1.36%. Regarding short-term risk, HCA is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check AVAH's competition here
HCA vs ARDT Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ARDT has a market cap of 1.4B. Regarding current trading prices, HCA is priced at $526.52, while ARDT trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ARDT's P/E ratio is 6.50. In terms of profitability, HCA's ROE is -1.41%, compared to ARDT's ROE of +0.17%. Regarding short-term risk, HCA is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check ARDT's competition here
HCA vs USPH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, USPH has a market cap of 1.3B. Regarding current trading prices, HCA is priced at $526.52, while USPH trades at $82.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas USPH's P/E ratio is 35.00. In terms of profitability, HCA's ROE is -1.41%, compared to USPH's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check USPH's competition here
HCA vs BKDT Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, HCA is priced at $526.52, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas BKDT's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, HCA is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check BKDT's competition here
HCA vs INNV Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, INNV has a market cap of 1.2B. Regarding current trading prices, HCA is priced at $526.52, while INNV trades at $8.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas INNV's P/E ratio is 178.40. In terms of profitability, HCA's ROE is -1.41%, compared to INNV's ROE of -0.02%. Regarding short-term risk, HCA is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check INNV's competition here
HCA vs PNTG Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, HCA is priced at $526.52, while PNTG trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas PNTG's P/E ratio is 42.64. In terms of profitability, HCA's ROE is -1.41%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, HCA is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check PNTG's competition here
HCA vs ASTH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ASTH has a market cap of 964M. Regarding current trading prices, HCA is priced at $526.52, while ASTH trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ASTH's P/E ratio is 101.16. In terms of profitability, HCA's ROE is -1.41%, compared to ASTH's ROE of +0.01%. Regarding short-term risk, HCA is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check ASTH's competition here
HCA vs FSHCX Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, FSHCX has a market cap of 806M. Regarding current trading prices, HCA is priced at $526.52, while FSHCX trades at $98.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas FSHCX's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to FSHCX's ROE of N/A. Regarding short-term risk, HCA is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check FSHCX's competition here
HCA vs AMN Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AMN has a market cap of 784M. Regarding current trading prices, HCA is priced at $526.52, while AMN trades at $20.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AMN's P/E ratio is -2.83. In terms of profitability, HCA's ROE is -1.41%, compared to AMN's ROE of -0.15%. Regarding short-term risk, HCA is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AMN's competition here
HCA vs CMPS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CMPS has a market cap of 767.1M. Regarding current trading prices, HCA is priced at $526.52, while CMPS trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CMPS's P/E ratio is -2.94. In terms of profitability, HCA's ROE is -1.41%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, HCA is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CMPS's competition here
HCA vs TALK Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TALK has a market cap of 755.3M. Regarding current trading prices, HCA is priced at $526.52, while TALK trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TALK's P/E ratio is 150.33. In terms of profitability, HCA's ROE is -1.41%, compared to TALK's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check TALK's competition here
HCA vs EHAB Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, EHAB has a market cap of 688.4M. Regarding current trading prices, HCA is priced at $526.52, while EHAB trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas EHAB's P/E ratio is -56.58. In terms of profitability, HCA's ROE is -1.41%, compared to EHAB's ROE of -0.02%. Regarding short-term risk, HCA is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check EHAB's competition here
HCA vs SNDA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SNDA has a market cap of 653.7M. Regarding current trading prices, HCA is priced at $526.52, while SNDA trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SNDA's P/E ratio is -11.65. In terms of profitability, HCA's ROE is -1.41%, compared to SNDA's ROE of -0.44%. Regarding short-term risk, HCA is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check SNDA's competition here
HCA vs CYH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CYH has a market cap of 484.1M. Regarding current trading prices, HCA is priced at $526.52, while CYH trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CYH's P/E ratio is 1.43. In terms of profitability, HCA's ROE is -1.41%, compared to CYH's ROE of -0.32%. Regarding short-term risk, HCA is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CYH's competition here
HCA vs MCTA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, HCA is priced at $526.52, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas MCTA's P/E ratio is 419.36. In terms of profitability, HCA's ROE is -1.41%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, HCA is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check MCTA's competition here
HCA vs AUNA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AUNA has a market cap of 381.3M. Regarding current trading prices, HCA is priced at $526.52, while AUNA trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AUNA's P/E ratio is 5.26. In terms of profitability, HCA's ROE is -1.41%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, HCA is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AUNA's competition here
HCA vs AONC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, HCA is priced at $526.52, while AONC trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AONC's P/E ratio is -13.48. In terms of profitability, HCA's ROE is -1.41%, compared to AONC's ROE of -0.02%. Regarding short-term risk, HCA is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check AONC's competition here
HCA vs CCRN Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CCRN has a market cap of 286.3M. Regarding current trading prices, HCA is priced at $526.52, while CCRN trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CCRN's P/E ratio is -17.84. In terms of profitability, HCA's ROE is -1.41%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, HCA is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check CCRN's competition here
HCA vs TOI Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TOI has a market cap of 253.8M. Regarding current trading prices, HCA is priced at $526.52, while TOI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TOI's P/E ratio is -4.03. In terms of profitability, HCA's ROE is -1.41%, compared to TOI's ROE of +21.04%. Regarding short-term risk, HCA is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check TOI's competition here
HCA vs CSU Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, HCA is priced at $526.52, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CSU's P/E ratio is 0.67. In terms of profitability, HCA's ROE is -1.41%, compared to CSU's ROE of -3.25%. Regarding short-term risk, HCA is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CSU's competition here
HCA vs AGL Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AGL has a market cap of 163.9M. Regarding current trading prices, HCA is priced at $526.52, while AGL trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AGL's P/E ratio is -0.51. In terms of profitability, HCA's ROE is -1.41%, compared to AGL's ROE of -0.73%. Regarding short-term risk, HCA is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AGL's competition here
HCA vs JYNT Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, JYNT has a market cap of 138.4M. Regarding current trading prices, HCA is priced at $526.52, while JYNT trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas JYNT's P/E ratio is -911.00. In terms of profitability, HCA's ROE is -1.41%, compared to JYNT's ROE of -0.04%. Regarding short-term risk, HCA is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check JYNT's competition here
HCA vs NAKAW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, HCA is priced at $526.52, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas NAKAW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to NAKAW's ROE of -0.74%. Regarding short-term risk, HCA is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check NAKAW's competition here
HCA vs AIRS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AIRS has a market cap of 107.7M. Regarding current trading prices, HCA is priced at $526.52, while AIRS trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AIRS's P/E ratio is -5.75. In terms of profitability, HCA's ROE is -1.41%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, HCA is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AIRS's competition here
HCA vs BTMD Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, BTMD has a market cap of 98.6M. Regarding current trading prices, HCA is priced at $526.52, while BTMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas BTMD's P/E ratio is 2.61. In terms of profitability, HCA's ROE is -1.41%, compared to BTMD's ROE of -0.33%. Regarding short-term risk, HCA is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check BTMD's competition here
HCA vs FVE Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, HCA is priced at $526.52, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas FVE's P/E ratio is -5.64. In terms of profitability, HCA's ROE is -1.41%, compared to FVE's ROE of -0.15%. Regarding short-term risk, HCA is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check FVE's competition here
HCA vs KDLYW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, HCA is priced at $526.52, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas KDLYW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, HCA is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check KDLYW's competition here
HCA vs DCGO Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, DCGO has a market cap of 72.6M. Regarding current trading prices, HCA is priced at $526.52, while DCGO trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas DCGO's P/E ratio is -1.40. In terms of profitability, HCA's ROE is -1.41%, compared to DCGO's ROE of -0.17%. Regarding short-term risk, HCA is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check DCGO's competition here
HCA vs ALR Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, HCA is priced at $526.52, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ALR's P/E ratio is -1.11. In terms of profitability, HCA's ROE is -1.41%, compared to ALR's ROE of -0.15%. Regarding short-term risk, HCA is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check ALR's competition here
HCA vs IMAC Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, HCA is priced at $526.52, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas IMAC's P/E ratio is -2.27. In terms of profitability, HCA's ROE is -1.41%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, HCA is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check IMAC's competition here
HCA vs CCEL Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CCEL has a market cap of 27.4M. Regarding current trading prices, HCA is priced at $526.52, while CCEL trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CCEL's P/E ratio is -56.75. In terms of profitability, HCA's ROE is -1.41%, compared to CCEL's ROE of -0.03%. Regarding short-term risk, HCA is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check CCEL's competition here
HCA vs AIH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, HCA is priced at $526.52, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AIH's P/E ratio is -2.78. In terms of profitability, HCA's ROE is -1.41%, compared to AIH's ROE of +1.16%. Regarding short-term risk, HCA is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AIH's competition here
HCA vs AMS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, AMS has a market cap of 14.3M. Regarding current trading prices, HCA is priced at $526.52, while AMS trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas AMS's P/E ratio is -6.20. In terms of profitability, HCA's ROE is -1.41%, compared to AMS's ROE of -0.09%. Regarding short-term risk, HCA is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check AMS's competition here
HCA vs CANO Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, HCA is priced at $526.52, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CANO's P/E ratio is -0.01. In terms of profitability, HCA's ROE is -1.41%, compared to CANO's ROE of -1.49%. Regarding short-term risk, HCA is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CANO's competition here
HCA vs FTRP Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, HCA is priced at $526.52, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas FTRP's P/E ratio is -1.22. In terms of profitability, HCA's ROE is -1.41%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, HCA is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check FTRP's competition here
HCA vs TOIIW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TOIIW has a market cap of 8.4M. Regarding current trading prices, HCA is priced at $526.52, while TOIIW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TOIIW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to TOIIW's ROE of +21.04%. Regarding short-term risk, HCA is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check TOIIW's competition here
HCA vs PIII Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, PIII has a market cap of 6.8M. Regarding current trading prices, HCA is priced at $526.52, while PIII trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas PIII's P/E ratio is -0.04. In terms of profitability, HCA's ROE is -1.41%, compared to PIII's ROE of -3.18%. Regarding short-term risk, HCA is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check PIII's competition here
HCA vs MODV Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, HCA is priced at $526.52, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas MODV's P/E ratio is -0.03. In terms of profitability, HCA's ROE is -1.41%, compared to MODV's ROE of +1.84%. Regarding short-term risk, HCA is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check MODV's competition here
HCA vs GBNH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, HCA is priced at $526.52, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas GBNH's P/E ratio is -0.06. In terms of profitability, HCA's ROE is -1.41%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, HCA is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check GBNH's competition here
HCA vs RHE Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, HCA is priced at $526.52, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas RHE's P/E ratio is -1.79. In terms of profitability, HCA's ROE is -1.41%, compared to RHE's ROE of +0.06%. Regarding short-term risk, HCA is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check RHE's competition here
HCA vs RHE-PA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, HCA is priced at $526.52, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, HCA's ROE is -1.41%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, HCA is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check RHE-PA's competition here
HCA vs TALKW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TALKW has a market cap of 3.3M. Regarding current trading prices, HCA is priced at $526.52, while TALKW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TALKW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check TALKW's competition here
HCA vs ATIP Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, HCA is priced at $526.52, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas ATIP's P/E ratio is -0.03. In terms of profitability, HCA's ROE is -1.41%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, HCA is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check ATIP's competition here
HCA vs IMACW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, HCA is priced at $526.52, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas IMACW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, HCA is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check IMACW's competition here
HCA vs SYRA Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SYRA has a market cap of 1M. Regarding current trading prices, HCA is priced at $526.52, while SYRA trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SYRA's P/E ratio is -1.12. In terms of profitability, HCA's ROE is -1.41%, compared to SYRA's ROE of -0.51%. Regarding short-term risk, HCA is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check SYRA's competition here
HCA vs MNDR Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, MNDR has a market cap of 823K. Regarding current trading prices, HCA is priced at $526.52, while MNDR trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas MNDR's P/E ratio is -0.05. In terms of profitability, HCA's ROE is -1.41%, compared to MNDR's ROE of -1.29%. Regarding short-term risk, HCA is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check MNDR's competition here
HCA vs CCM Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, CCM has a market cap of 479.1K. Regarding current trading prices, HCA is priced at $526.52, while CCM trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas CCM's P/E ratio is -0.61. In terms of profitability, HCA's ROE is -1.41%, compared to CCM's ROE of +0.07%. Regarding short-term risk, HCA is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check CCM's competition here
HCA vs BACK Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, BACK has a market cap of 233.5K. Regarding current trading prices, HCA is priced at $526.52, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas BACK's P/E ratio is -0.02. In terms of profitability, HCA's ROE is -1.41%, compared to BACK's ROE of +1.05%. Regarding short-term risk, HCA is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check BACK's competition here
HCA vs NVOS Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, HCA is priced at $526.52, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas NVOS's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, HCA is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check NVOS's competition here
HCA vs NIVFW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, NIVFW has a market cap of 35.3K. Regarding current trading prices, HCA is priced at $526.52, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas NIVFW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, HCA is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check NIVFW's competition here
HCA vs PIIIW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, PIIIW has a market cap of 15.3K. Regarding current trading prices, HCA is priced at $526.52, while PIIIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas PIIIW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, HCA is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check PIIIW's competition here
HCA vs IONM Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, IONM has a market cap of 313. Regarding current trading prices, HCA is priced at $526.52, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas IONM's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to IONM's ROE of +5.28%. Regarding short-term risk, HCA is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check IONM's competition here
HCA vs TVTY Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TVTY's P/E ratio is 19.06. In terms of profitability, HCA's ROE is -1.41%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, HCA is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check TVTY's competition here
HCA vs DCGOW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas DCGOW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to DCGOW's ROE of -0.17%. Regarding short-term risk, HCA is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check DCGOW's competition here
HCA vs TLMDW Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TLMDW's P/E ratio is N/A. In terms of profitability, HCA's ROE is -1.41%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, HCA is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check TLMDW's competition here
HCA vs TLMD Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas TLMD's P/E ratio is -1.60. In terms of profitability, HCA's ROE is -1.41%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, HCA is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check TLMD's competition here
HCA vs SLHGP Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, HCA's ROE is -1.41%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, HCA is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check SLHGP's competition here
HCA vs HNGR Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas HNGR's P/E ratio is 19.71. In terms of profitability, HCA's ROE is -1.41%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, HCA is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check HNGR's competition here
HCA vs DVCR Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas DVCR's P/E ratio is 28.34. In terms of profitability, HCA's ROE is -1.41%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, HCA is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check DVCR's competition here
HCA vs SLHG Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas SLHG's P/E ratio is -1.48. In terms of profitability, HCA's ROE is -1.41%, compared to SLHG's ROE of N/A. Regarding short-term risk, HCA is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for HCA.Check SLHG's competition here
HCA vs NFH Comparison February 2026
HCA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCA stands at 117.7B. In comparison, NFH has a market cap of 0. Regarding current trading prices, HCA is priced at $526.52, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCA currently has a P/E ratio of 18.59, whereas NFH's P/E ratio is -19.75. In terms of profitability, HCA's ROE is -1.41%, compared to NFH's ROE of -0.06%. Regarding short-term risk, HCA is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for HCA.Check NFH's competition here